#zepbound

Updated August 5, 2026: Added Lilly's ClinicalTrials.gov expanded-access record (NCT07629401), registered June 5, 2026, which lists no eligibility criteria. Biologic classification lawsuit context (Lilly v. FDA, Case 1:24-cv-01503). Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. NDA expected Q4 2026. Court ruling: FDA's bright-line classification of retatrutide as a drug (not biologic) vacated. Outcome determines whether compounding can legally exist post-approval.

Serena Williams disclosed GLP-1 treatment and a commercial Ro relationship in 2025, then returned to professional tennis in 2026. No cited official source confirms current Zepbound use. Here is the dated evidence and the difference between WADA monitoring and prohibition.

Updated July 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the SURMOUNT-5 head-to-head trial (NEJM 2024): a 47% greater relative reduction confirmed by 2026 systematic meta-analyses. Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Full cost and side-effect comparison.

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25 to $1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299 to 449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo, live as of July 2026. Prices verified July 2026 across 53 providers.

Updated July 2026: Medicare Part D now covers Foundayo, Wegovy, and Zepbound for weight loss (live since July 1, 2026) via the Medicare GLP-1 Bridge program. Flat $50/month copay. About 3.8 million Part D enrollees are eligible (KFF, June 2026). Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

Medicare GLP-1 coverage is NOW LIVE as of July 1, 2026. Here's who qualifies for the $50/month Bridge program, how to get prior auth, and whether the Bridge beats cash-pay (our 54-provider price audit).

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Verified July 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Verified July 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Verified July 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Verified July 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Verified August 2026: Tirzepatide prices include $149/mo via Gala on a yearly microdose plan ($169/mo for 3 months), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $399 for the 5mg vial, $449 for 7.5mg and higher doses when refill conditions are met, $25/mo with an eligible Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 54 tracked providers.

Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025. This guide compares advertised compounded prices with brand Zepbound and explains why legality, formulation, and safety cannot be inferred from availability alone.

Verified July 2026: Zepbound savings card cuts copay to $25/fill ($1,300 max annual savings) with commercial insurance. Mounjaro savings card offers $25 copay for T2D. Both expire Dec 31, 2026. Activate in 2 minutes at zepbound.lilly.com/savings. Full eligibility + backup options.